MarketCapExport financials
Haemonetics Corporation (HAE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Haemonetics Corporation HAE
$ 106.82
0.01%
Facebook
X
Telegram
Haemonetics Corporation Income Statement 2026-2008 | HAE
Brief overview of profit and loss at Haemonetics Corporation
This overview is based on financial performance over the past five years. Haemonetics Corporation reported revenue of 870 million dollars in 2021 and 1.3 billion dollars by 2026. The five-year change reached +53.3%, while CAGR stood at 8.9%. Sales increased steadily, although without strong acceleration.
At the gross-profit level, the result moved from 398 million dollars to 788 million dollars, a change of +98%. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. At the margin level, the figure shifted from 45.7% to 59%. Improving gross profitability strengthens the quality of revenue growth.
The five-year EBITDA result moved by +54.3%: from 174 million dollars to 268 million dollars. The operating result changed at a rate similar to sales. EBITDA margin moved from 20% to 20.1%. Operating profitability remained broadly stable.
Net profit was $79.5 million at the start and $97.3 million at the end. Net earnings remained broadly steady over the period.
Over the period, capitalization shifted from $2.5 billion to $2.8 billion (+14.7%). The market broadly confirmed the positive direction of the business.
Overall conclusion
The five-year financial profile is predominantly positive. The constructive conclusion rests on a steady EBITDA margin, a stronger final result and a stronger gross margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Haemonetics Corporation
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.81 B | 3.06 B | 4.7 B | 4.24 B | 4.26 B | 2.45 B | 6.16 B | 4.64 B | 4.12 B | 2.2 B | 1.41 B | 2.17 B | 1.63 B | 2.05 B | 1.82 B | 1.76 B | 682 M | 694 M | - |
Shares |
47.2 M | 50.3 M | 50.7 M | 50.8 M | 51 M | 50.7 M | 51.8 M | 52.9 M | 52.8 M | 51.5 M | 50.9 M | 52.1 M | 52.4 M | 52.3 M | 50.7 M | 51.2 M | 25.5 M | 25.4 M | - |
Historical Prices |
59.6 | 60.9 | 92.6 | 83.5 | 83.5 | 48.4 | 114 | 107 | 98.9 | 64.7 | 39.9 | 31.6 | 39.6 | 37.9 | 41.9 | 32.5 | 26.8 | 27.3 | 27.9 |
Net Income |
97.3 M | 168 M | 118 M | 115 M | 43.4 M | 79.5 M | 76.5 M | 55 M | 45.6 M | -26.3 M | -55.6 M | 16.9 M | 35.1 M | 38.8 M | 66.9 M | 80 M | 21.3 M | 59.3 M | - |
Revenue |
1.33 B | 1.36 B | 1.31 B | 1.17 B | 993 M | 870 M | 988 M | 968 M | 904 M | 886 M | 909 M | 910 M | 938 M | 892 M | 728 M | 677 M | 645 M | - | - |
Cost of Revenue |
546 M | 612 M | 618 M | 554 M | 488 M | 473 M | 504 M | 550 M | 492 M | 508 M | - | - | - | - | - | - | - | - | - |
Gross Profit |
788 M | 749 M | 692 M | 615 M | 506 M | 398 M | 488 M | 439 M | 412 M | 378 M | 406 M | 434 M | 468 M | 428 M | 369 M | 355 M | 87.8 M | 308 M | - |
Operating Income |
157 M | 222 M | 165 M | 156 M | 80.8 M | 89.7 M | 103 M | 83.5 M | 56.2 M | -19.4 M | -43.9 M | 40.5 M | 46.4 M | 56.4 M | 88.8 M | 111 M | 28.9 M | 85.6 M | - |
Interest Expense |
-28.7 M | -9.75 M | -13 M | -14.6 M | -17.1 M | -16.8 M | -16.2 M | -9.91 M | -4.52 M | -8.1 M | -9.47 M | -9.38 M | -10 M | -6.54 M | 740 K | 6 K | 742 K | 64 K | - |
EBITDA |
268 M | 337 M | 262 M | 249 M | 178 M | 174 M | 214 M | 193 M | 145 M | 70.4 M | 46 M | 127 M | 129 M | 122 M | 139 M | 159 M | 72.1 M | 122 M | - |
Operating Expenses |
631 M | 527 M | 527 M | 459 M | 425 M | 308 M | 384 M | 355 M | 356 M | 398 M | 450 M | 394 M | 421 M | 372 M | 280 M | 245 M | 254 M | 223 M | - |
General and Administrative Expenses |
442 M | 437 M | 430 M | 377 M | 340 M | 275 M | 284 M | 285 M | 317 M | 302 M | 317 M | 259 M | 365 M | 323 M | 245 M | 206 M | 214 M | 199 M | - |
All numbers in USD currency
Quarterly Income Statement Haemonetics Corporation
| 2027-Q1 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
45.4 M | 46.8 M | 47.6 M | 48.1 M | 46.8 M | 47.6 M | 48.1 M | 48.2 M | 50.3 M | 50.9 M | 50.9 M | 50.8 M | 50.8 M | 50.7 M | 50.5 M | 50.4 M | 50.5 M | 51 M | 51.2 M | 51.1 M | - | 51 M | 51 M | 50.9 M | 50.8 M | 50.8 M | 50.7 M | 50.4 M | 50.6 M | 50.6 M | 50.8 M | 51 M | 51.4 M | 51.4 M | 51.6 M | 52.3 M | 53.1 M | 52.6 M | 52.4 M | 52.3 M | 51.7 M | 51.4 M | 51.2 M | 50.9 M | 50.7 M | 50.9 M | 51 M | 51.7 M | 51.4 M | 51.5 M | 51.6 M | 52 M | 51.7 M | 51.5 M | 51.4 M | 51 M | 51.7 M | 51.4 M | 51.2 M | 50.6 M | 50.2 M | 50.8 M | 25.6 M | 25.3 M | 25 M | 24.7 M | 25.1 M |
Net Income |
33 M | 44.7 M | 38.7 M | 34 M | 44.7 M | 38.7 M | 34 M | - | 37.5 M | 33.8 M | 38.4 M | - | 31.2 M | 24.9 M | 41 M | - | 32.9 M | 33.2 M | 19.9 M | - | - | 14.9 M | -4.45 M | -4.45 M | 31.9 M | 31.9 M | 48.1 M | 10.5 M | 29.9 M | 29.9 M | 37.5 M | -8.48 M | -8.48 M | 18.3 M | 18.7 M | 11.9 M | -6.55 M | 20.1 M | 20.1 M | 20.1 M | 15.4 M | 15.4 M | 19.8 M | -10.3 M | -59.4 M | -59.4 M | 12.9 M | -267 K | 16 M | 16 M | 7.49 M | -3.65 M | 16.3 M | 16.3 M | 16.5 M | -7.87 M | 9.9 M | 9.9 M | 6.55 M | 9.79 M | 18.3 M | 18.3 M | 13.9 M | 16.9 M | 19.7 M | 21.3 M | 17.9 M |
Revenue |
339 M | 339 M | 327 M | 321 M | 339 M | 327 M | 321 M | - | 349 M | 346 M | 336 M | - | 336 M | 318 M | 311 M | - | 305 M | 297 M | 261 M | - | - | 240 M | 468 M | 225 M | 240 M | 240 M | 209 M | 196 M | 259 M | 259 M | 253 M | 238 M | 247 M | 247 M | 242 M | 234 M | 234 M | 225 M | 211 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
137 M | 137 M | 133 M | 129 M | 137 M | 133 M | 129 M | - | 155 M | 158 M | 161 M | - | 158 M | 148 M | 144 M | - | 147 M | 140 M | 119 M | - | - | 117 M | 238 M | - | 120 M | 120 M | 104 M | 106 M | 131 M | 131 M | 126 M | 123 M | 136 M | 136 M | 130 M | - | 123 M | 121 M | 119 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
203 M | 202 M | 195 M | 192 M | 202 M | 195 M | 192 M | - | 194 M | 187 M | 175 M | - | 178 M | 171 M | 167 M | - | 159 M | 158 M | 142 M | - | - | 123 M | 231 M | 81.8 M | 120 M | 120 M | 106 M | 90 M | 128 M | 128 M | 127 M | 116 M | 111 M | 111 M | 112 M | 104 M | 111 M | 105 M | 91.7 M | 91.7 M | 101 M | 101 M | 104 M | 91.1 M | 109 M | 109 M | 105 M | 103 M | 112 M | 112 M | 108 M | 106 M | 122 M | 122 M | 120 M | 111 M | 113 M | 113 M | 102 M | 90.1 M | 95.9 M | 95.9 M | 89.9 M | 88.7 M | 93.5 M | 87.8 M | 86.5 M |
Operating Income |
57.5 M | 67.4 M | 58.5 M | 53.9 M | 67.4 M | 58.5 M | 53.9 M | - | 59 M | 51.7 M | 39.8 M | - | 46 M | 35.3 M | 53.7 M | - | 43.3 M | 46.7 M | 30.8 M | - | - | 24.5 M | 25.9 M | -21.2 M | 40.4 M | 40.4 M | 58.8 M | 11.7 M | 40.9 M | 40.9 M | 49.7 M | -13.3 M | 28.3 M | 28.3 M | 26.1 M | 14.3 M | 1.01 M | 24.3 M | 16.6 M | 16.6 M | 21.2 M | 21.2 M | 24.8 M | -7.88 M | -61.2 M | -61.2 M | 19.2 M | 3.61 M | 18.3 M | 18.3 M | 12.4 M | -1.67 M | 17.6 M | 17.9 M | 23.4 M | -6.61 M | 15.7 M | 15.7 M | 9.9 M | 13.1 M | 25.3 M | 25.3 M | 18.6 M | 23.9 M | 28.6 M | 28.9 M | 24.2 M |
Interest Expense |
-9.88 M | -7.42 M | -7.21 M | -8.7 M | -7.42 M | -7.21 M | -8.7 M | - | -9.11 M | -6.99 M | 6.96 M | - | -1.95 M | -2.47 M | -2.07 M | - | -1.06 M | -5.67 M | -5.27 M | - | - | -4.59 M | -8.99 M | - | -3.05 M | -3.05 M | -3.83 M | -3.74 M | -3.08 M | -3.08 M | -4.65 M | -4.42 M | -2.86 M | -2.86 M | -3.04 M | - | -806 K | -1.4 M | -1.36 M | - | -2.28 M | -6.41 M | -4.14 M | - | -2.14 M | -6.76 M | -4.62 M | - | -2.31 M | -7.5 M | -5.19 M | - | -2.85 M | -8.04 M | -5.18 M | - | -2.54 M | -3.52 M | -975 K | - | 111 K | 370 K | 106 K | - | 111 K | 23 K | 153 K |
EBITDA |
84.6 M | 94.8 M | 86.7 M | 82.6 M | 94.8 M | 86.7 M | 82.6 M | - | 88.1 M | 80.9 M | 68.9 M | - | 60.2 M | 48.9 M | 76.7 M | - | 56.4 M | 59.6 M | 53.2 M | - | - | 35.9 M | 74.5 M | -21.2 M | 48.2 M | 103 M | 100 M | 32.4 M | 40.9 M | 122 M | 104 M | 14.1 M | 28.3 M | 108 M | 77.8 M | 14.3 M | 1.01 M | 24.3 M | 38.4 M | 16.6 M | 21.2 M | 88.7 M | 70 M | -7.88 M | -61.2 M | 6.54 M | 64.2 M | 3.61 M | 18.3 M | 82.2 M | 54 M | -1.67 M | 17.6 M | 76.9 M | 61.7 M | -6.61 M | 15.7 M | 62.5 M | 38.5 M | 13.1 M | 25.3 M | 62.6 M | 43.2 M | 23.9 M | 65.6 M | 53.6 M | 36.6 M |
Operating Expenses |
145 M | 135 M | 136 M | 138 M | 135 M | 136 M | 138 M | - | 135 M | 136 M | 135 M | - | 132 M | 135 M | 114 M | - | 115 M | 111 M | 111 M | - | - | 98 M | 205 M | - | 79.8 M | 79.8 M | 47 M | 78.3 M | 87.1 M | 87.1 M | 77.3 M | 129 M | 82.9 M | 82.9 M | 85.8 M | - | 110 M | 80.3 M | 75.1 M | - | 79.9 M | 258 M | 178 M | - | 170 M | 355 M | 185 M | - | 93.4 M | 297 M | 204 M | - | 104 M | 318 M | 214 M | - | 97.4 M | 266 M | 169 M | - | 70.6 M | 207 M | 136 M | - | 64.9 M | 58.8 M | 62.3 M |
General and Administrative Expenses |
119 M | 109 M | 102 M | 111 M | 109 M | 102 M | 111 M | - | 106 M | 107 M | 108 M | - | 112 M | 115 M | 93.5 M | - | 94.7 M | 92 M | 92.2 M | - | - | 75.8 M | 167 M | - | 65.6 M | 73.4 M | 71.7 M | 69.5 M | 78.3 M | 78.3 M | 69.8 M | 73 M | 73.9 M | 73.9 M | 77.2 M | - | 97.9 M | 72.8 M | 66.9 M | - | 71.4 M | 230 M | 159 M | - | 78.9 M | 241 M | 162 M | - | 82.5 M | 259 M | 177 M | - | 89.6 M | 278 M | 188 M | - | 86.8 M | 235 M | 149 M | - | 61.4 M | 180 M | 119 M | - | 56.9 M | 52.8 M | 54.4 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Haemonetics Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |